Latest News

Effect of Ionic Shield on SARS-CoV-2 Inactivation: A Pilot Study in the Hospital Environment

The spread of the new coronavirus SARS-CoV-2 has substantial social, health, and economic impacts. High viral load in the air in hospitals poses a risk to medical personnel.

Cold atmospheric plasma (CAP) is a new technology based on the emission in the air of reactive species, neutral particles, UV radiation, and electromagnetic field. CAP has the potential as an antiviral agent.

In this study, an 80-day clinical trial took place at Nicosia General Hospital to evaluate the application of CAP devices for lowering the viral load in the COVID rooms. A total of 284 indoor environment samples were tested by RT-PCR, for which 9 were positive (~3% Positive Rate).

After analyzing the initial results, an ion emitter was paired with each patient, and the results showed that the method could eliminate the virus from the COVID wards up to 100%. The number of patients discharged from the hospital in the ionizer group was 4.8% higher than in the non-ionizer group, and 45% fewer patients in the ionizer group who remained in the rooms required oxygen support.

The clinical trial shows evidence that composite CAP can decrease coronavirus spread in hospital environments and potentially prevent virus transmission.

Full text of the study is available on the following link: COVID | Free Full-Text | Effect of Cold Atmospheric Plasma on SARS-CoV-2 Inactivation: A Pilot Study in the Hospital Environment (